Rallybio (RLYB) Cash from Financing Activities (2020 - 2026)
Rallybio (RLYB) posted Cash from Financing Activities of $3000.0 for Q1 2026, down 50.0% sequentially from $6000.0 in Q4 2025.
Rallybio (RLYB) Cash from Financing Activities (2020 - 2026) Analysis & Trends
Rallybio has reported Cash from Financing Activities for 7 years, with the latest figure at $3000.0 in Q1 2026.
- Quarterly Cash from Financing Activities changed N/A year-over-year to $3000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $19000.0 (down 99.63% YoY) and the FY2025 annual result came in at $16000.0, down 99.69% from the prior year.
- Cash from Financing Activities eased to $3000.0 in Q1 2026 per RLYB's latest filing, from $6000.0 in the prior quarter.
- Over five years, Cash from Financing Activities peaked at $51.2 million in Q4 2022 and troughed at -$139000.0 in Q1 2023.
- A 5-year average of $5.1 million and a median of $10000.0 in 2025 frame the typical range for Cash from Financing Activities.
- The widest YoY moves for Cash from Financing Activities: up 3255.89% in 2022, down 100.09% in 2022.
- Over 5 years, Cash from Financing Activities stood at $51.2 million in 2022, then tumbled by 99.86% to $72000.0 in 2023, then slumped by 75.0% to $18000.0 in 2024, then slumped by 66.67% to $6000.0 in 2025, then slumped by 50.0% to $3000.0 in 2026.
- According to Business Quant data, Cash from Financing Activities over the past three periods registered $3000.0, $6000.0, and $10000.0 for Q1 2026, Q4 2025, and Q2 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 14.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -6.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 36.24 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -16.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 27.18 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -273.15 Mn |
| 10 | Rallybio | 94.61 Mn | 94.61 Mn | - | 131,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 131,000.00 |
| Jun 30, 2026 | 131,000.00 |
| Mar 31, 2026 | 3,000.00 |
| Mar 31, 2026 | 3,000.00 |
| Dec 31, 2025 | 6,000.00 |
| Dec 31, 2025 | 6,000.00 |
| Jun 30, 2025 | 10,000.00 |
| Jun 30, 2025 | 10,000.00 |
| Dec 31, 2024 | 18,000.00 |
| Dec 31, 2024 | 18,000.00 |
| Sep 30, 2024 | -11,000.00 |
| Sep 30, 2024 | -11,000.00 |
| Jun 30, 2024 | 5.19 Mn |
| Jun 30, 2024 | 5.19 Mn |
| Dec 31, 2023 | 72,000.00 |
| Dec 31, 2023 | 72,000.00 |
| Jun 30, 2023 | 210,000.00 |
| Jun 30, 2023 | 210,000.00 |
| Mar 31, 2023 | -139,000.00 |
| Mar 31, 2023 | -139,000.00 |